Zynex Sets Third Quarter 2025 Earnings Call
Rhea-AI Summary
Zynex (NASDAQ: ZYXI) will host its Q3 2025 earnings conference call on Tuesday, November 18, 2025 at 9:00 AM ET (7:00 AM MT) to discuss results for the quarter ended September 30, 2025. A press release with financial results will be issued prior to the call. Management will host the call and provide a live webcast.
Dial-in numbers are U.S. & Canada: 800-836-8184 and International: 646-357-8785. A webcast link will be available at https://zynexmed.investorroom.com/. Callers are asked to dial in 5–10 minutes early.
Positive
- None.
Negative
- None.
News Market Reaction 24 Alerts
On the day this news was published, ZYXI declined 27.04%, reflecting a significant negative market reaction. Argus tracked a trough of -37.0% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $24M at that time. Trading volume was exceptionally heavy at 7.9x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Zynex management will host the conference call.
Date: Tuesday, November 18, 2025
Time: 9:00 AM Eastern Time (7:00 PM Mountain Time)
International number: 646-357-8785
Webcast: Q3 2025 Webcast Link
The Company will also provide a link at https://zynexmed.investorroom.com/ for those who wish to stream the call via webcast. Please call the conference telephone number 5-10 minutes prior to the start time.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Vikram Bajaj, CFO
ir@zynex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-sets-third-quarter-2025-earnings-call-302615402.html
SOURCE Zynex, Inc.